HK1149709A1 - Use of mva to treat prostate cancer mva - Google Patents

Use of mva to treat prostate cancer mva

Info

Publication number
HK1149709A1
HK1149709A1 HK11103921.5A HK11103921A HK1149709A1 HK 1149709 A1 HK1149709 A1 HK 1149709A1 HK 11103921 A HK11103921 A HK 11103921A HK 1149709 A1 HK1149709 A1 HK 1149709A1
Authority
HK
Hong Kong
Prior art keywords
mva
prostate cancer
treat prostate
recombinant mva
mva viruses
Prior art date
Application number
HK11103921.5A
Other languages
English (en)
Inventor
Alain Delcayre
Reiner Laus
Stefanie Mandl
Ryan Blair Rountree
Fatema Legrand
Original Assignee
Bavarian Nordic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bavarian Nordic Inc filed Critical Bavarian Nordic Inc
Publication of HK1149709A1 publication Critical patent/HK1149709A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/04—Uses of viruses as vector in vivo
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK11103921.5A 2007-10-18 2011-04-19 Use of mva to treat prostate cancer mva HK1149709A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96089307P 2007-10-18 2007-10-18
PCT/US2008/080229 WO2009052328A1 (en) 2007-10-18 2008-10-16 Use of mva to treat prostate cancer

Publications (1)

Publication Number Publication Date
HK1149709A1 true HK1149709A1 (en) 2011-10-14

Family

ID=40342626

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11103921.5A HK1149709A1 (en) 2007-10-18 2011-04-19 Use of mva to treat prostate cancer mva

Country Status (14)

Country Link
US (2) US7867483B2 (ja)
EP (1) EP2207564B1 (ja)
JP (1) JP5669581B2 (ja)
KR (2) KR20160065985A (ja)
CN (1) CN101888853B (ja)
AU (1) AU2008312444B2 (ja)
CA (1) CA2702586C (ja)
DK (1) DK2207564T3 (ja)
ES (1) ES2608604T3 (ja)
HK (1) HK1149709A1 (ja)
IL (1) IL204541A (ja)
NZ (2) NZ601827A (ja)
RU (1) RU2499606C2 (ja)
WO (1) WO2009052328A1 (ja)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
EP1598425A1 (en) * 2000-11-23 2005-11-23 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant
US8940871B2 (en) 2006-03-20 2015-01-27 The Regents Of The University Of California Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting
JP6126773B2 (ja) 2007-09-04 2017-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原（ｐｓｃａ）抗体
EP2740490A1 (en) * 2007-10-03 2014-06-11 Cornell University Treatment of proliferative disorders using antibodies to PSMA
KR20160065985A (ko) * 2007-10-18 2016-06-09 버베리안 노딕 에이/에스 전립선 암 치료를 위한 ｍｖａ의 용도
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
ES2712732T3 (es) * 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
GB2484058A (en) * 2009-12-01 2012-04-04 Uni Konstanz Prostate cancer DNA vaccine
EP2506876B1 (en) 2009-12-02 2016-10-12 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
EP2833150A4 (en) 2012-03-30 2016-03-23 Univ Kyoto URINBIOMARKER FOR USE IN A TEST ON PROSTATE CANCER
BR112016008806A2 (pt) 2013-11-01 2017-10-03 Pfizer Vetores para expressão de antígenos associados à próstata
BR112017005245A2 (pt) 2014-09-19 2017-12-12 Regeneron Pharma animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos.
WO2016144564A2 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
WO2016168862A1 (en) 2015-04-17 2016-10-20 Memorial Sloan-Kettering Cancer Center Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
EP4137158A1 (en) 2015-08-07 2023-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
FR3042121A1 (fr) 2015-10-08 2017-04-14 Jean-Marc Limacher Composition anti-tumorale
GB201520570D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US11000578B2 (en) * 2016-02-12 2021-05-11 Madison Vaccines Inc. Treatment of prostate cancer with pap vaccine and PD-1 inhibitor co-therapy
MX2018010204A (es) 2016-02-25 2019-05-06 Memorial Sloan Kettering Cancer Center Virus de la vaccinia atenuada competentes para replicacion con la supresion de timidina quinasa con y sin la expresion del flt3l o gm-csf humanos para inmunoterapia del cancer.
CN109152827B (zh) 2016-02-25 2023-07-21 纪念斯隆凯特琳癌症中心 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
US10703755B2 (en) * 2016-04-26 2020-07-07 Sumitomo Dainippon Pharma Co., Ltd. Substituted purine derivative
CN116458475A (zh) 2016-06-03 2023-07-21 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
AU2017274540B2 (en) * 2016-06-03 2020-04-16 Etubics Corporation Compositions and methods for tumor vaccination using prostate cancer-associated antigens
CN106084027A (zh) * 2016-06-24 2016-11-09 安徽未名细胞治疗有限公司 特异性肿瘤抗原EphA2的CTL识别表位肽及其应用
CN106119231A (zh) * 2016-06-24 2016-11-16 安徽未名细胞治疗有限公司 一种肿瘤抗原psa的ctl识别表位肽及其应用
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
US10925947B2 (en) * 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
JP2022536122A (ja) * 2019-06-07 2022-08-12 オレゴン ヘルス アンド サイエンス ユニバーシティ 腫瘍関連抗原特異的ｔ細胞応答
WO2021099906A1 (en) 2019-11-18 2021-05-27 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
US20210315986A1 (en) * 2020-04-13 2021-10-14 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
US20230029453A1 (en) * 2020-07-06 2023-02-02 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0596032B2 (en) * 1991-07-25 2004-04-07 Idec Pharmaceuticals Corporation Induction of cytotoxic t-lymphocyte responses
US5925362A (en) * 1993-08-11 1999-07-20 Jenner Technologies Method to elicit an antitumor response with human prostate-specific antigen
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
US6165460A (en) * 1995-07-10 2000-12-26 Therion Biologics Corporation Generation of immune responses to prostate-specific antigen (PSA)
US5882864A (en) * 1995-07-31 1999-03-16 Urocor Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
AU6897998A (en) 1997-04-11 1998-11-11 Dendreon Corporation Composition and method for inducing an immune response against tumour-rela ted antigens
HUP0103976A3 (en) 1998-10-05 2008-04-28 Pharmexa As Novel methods for therapeutic vaccination
CA2354024C (en) * 1998-12-09 2009-12-22 Jeffrey Schlom A recombinant vector expressing multiple costimulatory molecules and uses thereof
EP1598425A1 (en) 2000-11-23 2005-11-23 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant
WO2003073828A2 (en) * 2002-03-01 2003-09-12 Applied Immune Technologies Immunotherapy for prostate cancer using recombinant bacille calmette-guerin expressing prostate specific antigens
CN102703393A (zh) * 2002-05-16 2012-10-03 巴法里安诺迪克有限公司 表达插入痘病毒基因组中的同源基因的重组痘病毒
EP1660664A4 (en) * 2003-08-21 2008-02-13 Virax Dev Pty Ltd POXVIRUS VECTOR ENCODING SPECIFIC PROSTATE ANTIGENS FOR THE TREATMENT OF PROSTATE CANCER
BRPI0401465A (pt) 2004-04-20 2006-02-21 Embria Informatica Ltda sistema para administrar interações entre usuários e aplicações de software em um ambiente web
KR20160065985A (ko) 2007-10-18 2016-06-09 버베리안 노딕 에이/에스 전립선 암 치료를 위한 ｍｖａ의 용도

Also Published As

Publication number Publication date
NZ601827A (en) 2014-01-31
US8377688B2 (en) 2013-02-19
NZ584042A (en) 2012-09-28
CA2702586A1 (en) 2009-04-23
AU2008312444B2 (en) 2014-02-06
US7867483B2 (en) 2011-01-11
EP2207564A1 (en) 2010-07-21
US20110008386A1 (en) 2011-01-13
IL204541A0 (en) 2010-11-30
RU2499606C2 (ru) 2013-11-27
CN101888853A (zh) 2010-11-17
JP2011500718A (ja) 2011-01-06
JP5669581B2 (ja) 2015-02-12
KR101648087B1 (ko) 2016-08-17
US20090104225A1 (en) 2009-04-23
DK2207564T3 (en) 2017-01-16
KR20100109545A (ko) 2010-10-08
KR20160065985A (ko) 2016-06-09
CA2702586C (en) 2017-08-01
WO2009052328A1 (en) 2009-04-23
ES2608604T3 (es) 2017-04-12
EP2207564B1 (en) 2016-10-05
WO2009052328A8 (en) 2009-07-02
CN101888853B (zh) 2013-03-13
AU2008312444A1 (en) 2009-04-23
IL204541A (en) 2015-02-26
RU2010115220A (ru) 2011-11-27

Similar Documents

Publication Publication Date Title
HK1149709A1 (en) Use of mva to treat prostate cancer mva
SG194701A1 (en) Anti-cd40 antibodies and methods of use
WO2008045346A3 (en) Recombinant modified vaccinia ankara encoding a her-2 antigen for use in treating cancer
NZ707086A (en) Anti-cd40 antibodies and methods of use
WO2008076278A8 (en) Methods of cancer treatment with igf1r inhibitors
WO2012024530A3 (en) Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
MX2016004551A (es) Uso de moleculas de ligacion a semaforina-4d para el tratamiento de aterosclerosis.
WO2012006634A3 (en) Prostate specific antigen (psa) peptide therapy
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
MX341076B (es) Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
NZ606195A (en) Methods and compositions for liver cancer therapy
WO2014143807A3 (en) Anti-cd37 antibody and bcr pathway antagonist combination therapy for treatment of b-cell malignancies and disorders
WO2007053573A3 (en) Treatment of cancer with sorafenib
MX2011010390A (es) Conjugados, particulas, composiciones de agentes polimericos y metodos relacionados de uso.
WO2010118063A3 (en) Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
MX2009008132A (es) Terapia de combinacion con inhibidores de angiogenesis.
AU2011332810A8 (en) Anti-IL-6 antibodies for the treatment of oral mucositis
MX346924B (es) Compuestos de diarilhidantoina.
MY191825A (en) Therapeutic compounds and compositions
MY162903A (en) Methods of treatment of pancreatic cancer
MX342274B (es) Actividades de la piruvato quinasa m2 (pkm2).
MX2007011545A (es) Combinaciones para el tratamiento de cancer que comprenden el anticuerpo anti-egfr e inhibidores de vegfr.
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
WO2008030883A3 (en) Treatment of cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20191010